Literature DB >> 20858859

Clinically significant cardiac disease in patients with Hodgkin lymphoma treated with mediastinal irradiation.

Shira L Galper1, James B Yu, Peter M Mauch, Jon F Strasser, Barbara Silver, Ann Lacasce, Karen J Marcus, Mary Ann Stevenson, Ming Hui Chen, Andrea K Ng.   

Abstract

This study assessed the cumulative incidence of clinically significant cardiac disease in 1279 Hodgkin lymphoma patients treated with mediastinal irradiation and quantified the standard incidence ratios (SIRs) and absolute excess risks of cardiac procedures compared with a normal matched population. Cox regression analysis was used to explore factors associated with cardiac complications. Poisson regression analysis of SIRs was used to estimate the excess risk of cardiac interventions from mediastinal irradiation. After a median follow-up of 14.7 years, 187 patients experienced 636 cardiac events and 89 patients required a cardiac procedure. 5-, 10-, 15-, and 20-year cumulative incidence rates of cardiac events were 2.2%, 4.5%, 9.6%, and 16%. SIRs for cardiac procedures were increased for coronary artery bypass graft (3.19), percutaneous intervention (1.55), implantable cardioverter defibrillator or pacemaker placement (1.9), valve surgery (9.19), and pericardial surgery (12.91). Absolute excess risks were 18.2, 19.3, 9.4, 14.1, and 4.7 per 10 000 person-years, respectively. Older age at diagnosis and male sex were predictors for cardiac events. However, younger age at diagnosis was associated with excess risk specifically from radiation therapy compared with the general population. These results may help guideline development for both the types and timing of cardiac surveillance in survivors of Hodgkin lymphoma.

Entities:  

Mesh:

Year:  2010        PMID: 20858859     DOI: 10.1182/blood-2010-06-291328

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  67 in total

1.  Severe left main coronary stenosis in a young female patient, 6 years after mediastinal radiation therapy for non-Hodgkin lymphoma: assessment by coronary angiography and intravascular ultrasound.

Authors:  Grigorios Korosoglou; Arnt V Kristen; Martin Andrassy; Hugo A Katus; Stefan E Hardt
Journal:  Clin Res Cardiol       Date:  2012-04       Impact factor: 5.460

Review 2.  Appropriate surveillance for late complications in patients in remission from Hodgkin lymphoma.

Authors:  Deborah L Darrington; Julie M Vose
Journal:  Curr Hematol Malig Rep       Date:  2012-09       Impact factor: 3.952

Review 3.  Cancer Treatment-Associated Pericardial Disease: Epidemiology, Clinical Presentation, Diagnosis, and Management.

Authors:  Chandra K Ala; Allan L Klein; Javid J Moslehi
Journal:  Curr Cardiol Rep       Date:  2019-11-25       Impact factor: 2.931

Review 4.  Role of echocardiography in cancer care.

Authors:  J K Raikhelkar; R M Steingart; C L Chen
Journal:  Herz       Date:  2011-06       Impact factor: 1.443

Review 5.  Survivorship after allogeneic transplantation-management recommendations for the primary care provider.

Authors:  André Tichelli; Alicia Rovó
Journal:  Curr Hematol Malig Rep       Date:  2015-03       Impact factor: 3.952

6.  Pharmacogenomics meets precision cardio-oncology: is there synergistic potential?

Authors:  Jennifer K Hockings; Jessica A Castrillon; Feixiong Cheng
Journal:  Hum Mol Genet       Date:  2020-10-20       Impact factor: 6.150

7.  In Reply.

Authors:  Thorsten Derlin
Journal:  Dtsch Arztebl Int       Date:  2018-06-15       Impact factor: 5.594

8.  The case for combined-modality therapy for limited-stage Hodgkin's disease.

Authors:  Christine E Hill-Kayser; John P Plastaras; Zelig Tochner; Eli Glatstein
Journal:  Oncologist       Date:  2012-07-17

9.  Early Post-Therapy Prescription Drug Usage among Childhood and Adolescent Cancer Survivors.

Authors:  Andrew B Smitherman; Danielle Mohabir; Tania M Wilkins; Julie Blatt; Hazel B Nichols; Stacie B Dusetzina
Journal:  J Pediatr       Date:  2018-02-12       Impact factor: 4.406

10.  A Small Peptide Ac-SDKP Inhibits Radiation-Induced Cardiomyopathy.

Authors:  Umesh C Sharma; Swati D Sonkawade; Joseph A Spernyak; Sandra Sexton; Juliane Nguyen; Suraj Dahal; Kristopher M Attwood; Anurag K Singh; Jop H van Berlo; Saraswati Pokharel
Journal:  Circ Heart Fail       Date:  2018-08       Impact factor: 8.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.